AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ABT

Abbott Laboratories (ABT) Sees $23.9 Million in Net ETF Buying on Monday

Abbott Laboratories (ABT) experienced $23.9 million in net ETF buying on Monday, with 25 ETFs purchasing shares and 9 selling. The largest buyers were IHI, XLV, and DFLV. ABT's market cap is $178.4 billion, with a P/E of 38.06 and a dividend yield of 2.59%.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:06 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Laboratories (ABT) Sees $23.9 Million in Net ETF Buying on Monday — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ABTBullishLow
01

Why it matters

Net ETF buying can affect near-term demand and sentiment, but without new earnings, guidance, or regulatory/product catalysts, the effect is likely limited to positioning.

02

Market read

Traders may treat the flow snapback as a short-term supportive signal for ABT, but it is not a fundamental re-rating catalyst.

03

What to watch

The piece does not identify whether the buying is concentrated in passive/index exposure versus active tilts, nor does it quantify longer-horizon flows beyond the last few sessions.

Relevance 4/10Novelty 4/10Timing: reported for Monday’s ETF flow reversal

Background

The article describes Abbott’s recent ETF flow pattern, including a prior outflow on Oct. 23 and an inflow on Oct. 22.

Company-level read

Ticker impact

$ABTBullishMedium confidence
Context

Monday ETF flows turned positive for Abbott, with funds buying $23.9 million net as 25 ETFs added shares versus 9 sellers.

Expected impact

Likely mild upward bias or reduced downside pressure as traders interpret the flow snapback as supportive positioning.

Evidence & confidence

The article reports a specific, same-day ETF flow reversal and stake changes, which can influence short-term positioning, but it does not include new company fundamentals, guidance, or regulatory/product developments.

Market effects

Sector

Medical devices/healthcare ETFs may see modest relative support if ABT flows improve, but the article is single-name and flow-driven.

Regional

No direct regional macro linkage; impact is primarily US ETF positioning.

Global

Limited, since the catalyst is US-listed ETF activity rather than global fundamentals.

Counterpoint

What could challenge this read

ETF flow reversals can be transient and driven by index/rotation mechanics rather than a durable view on ABT fundamentals.

Key entities

  • company
    Abbott Laboratories

    Subject of the article, with $23.9 million net ETF buying reported for Monday.

  • ETF
    IHI

    Largest buyer by dollar value, adding $14.1 million and increasing its stake by 2.22%.

  • ETF
    XLV

    Second-largest buyer by dollar value, adding $9.5 million.

Read at source← All news

Related articles

$ABTMedAI 9/10

Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (ABT) presented positive clinical trial results for two cardiovascular devices at a conference. The Amulet 360 LAA Occluder showed 96.3% complete closure in patients, with low complication rates. The SonicForce System achieved 97% procedural success in treating calcified coronary arteries. ABT shares rose 2.55% to $108.91.

finance.yahoo.com
$ABTMedAI 8/10

More than 98% of study patients had no stroke of the most common kind or blood-clot complication for a year.

Abbott (NYSE: ABT) presented one-year results from the VERITAS study of its Amulet 360 LAA Occluder, showing 98% of patients had no stroke or blood-clot complications. The device aims to reduce stroke risk in atrial fibrillation patients. Over 99% of patients had no pericardial effusion requiring intervention, and 98% had no cardiovascular-related mortality. The Amulet 360 features enhanced design for better LAA closure.

stocktitan.net
$ABTMed

Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Abbott (NYSE: ABT) presented one-year data from the VERITAS study on its Amulet 360 LAA Occluder, showing 96.3% closure rates and low stroke incidence in atrial fibrillation patients. The device is designed to reduce stroke risk and is approved for investigational use in the U.S. and CE Mark in Europe.

prnewswire.com
$ABTMedAI 8/10

Scans found heart-artery calcium fractures after an investigational sound-wave treatment

Abbott's investigational SonicForce Coronary IVL System showed positive results in the TECTONIC study, meeting safety and effectiveness endpoints. The study enrolled 335 patients with severe coronary calcification, reporting a 0.3% 30-day target lesion failure rate and 97% procedural success. The system uses acoustic pressure waves to crack calcium buildup in coronary arteries, potentially expanding Abbott's cardiovascular portfolio.

stocktitan.net
$ABTMedAI 9/10

Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

Abbott (NYSE: ABT) reported positive 30-day results from its TECTONIC study of the investigational SonicForce Coronary IVL System, which met safety and effectiveness endpoints. The study showed a 0.3% target lesion failure rate and 97% procedural success in treating severe coronary calcification. The system uses acoustic pressure waves to crack calcium buildup in arteries, potentially expanding Abbott's portfolio of cardiovascular devices.

prnewswire.com